Mechanisms for Covid-19 Disease Complications

Conditions

Coronavirus Infection, COVID

Keywords

Covid-19, Biomarkers, Cardiovascular disease, Prognosis

Brief summary

Covid-19 is associated with a wide range of symptoms and clinical trajectories, and early identification of patients at risk for developing severe disease is desirable. Several risk markers and comorbidity profiles have been proposed but their relative importance in unselected patients admitted to hospital with Covid-19 remains unclear. This study aims to assess the prognostic value organ specific biomarkers, viral dynamics and immune response markers in patients infected with SARS-CoV2.

Torbjørn Omland, Christian Prebensen, Christine Monceyron Jonassen, My Svensson, Jan Erik Berdal et al. (7 authors)

Open Heart2021-12-0119 citations

10.1136/openhrt-2021-001884

Cardiac pathology 6 months after hospitalization for COVID-19 and association with the acute disease severity.

Myhre PL, Heck SL, Skranes JB, Prebensen C, Jonassen CM, Berge T, Mecinaj A, Melles W, Einvik G, Ingul CB, Tveit A, Berdal JE, Røsjø H, Lyngbakken MN, Omland T.

2021-08-1325 citations

10.1016/j.ahj.2021.08.001

SARS‐CoV‐2 Viremia is Associated With Inflammatory, But Not Cardiovascular Biomarkers, in Patients Hospitalized for COVID‐19

Peder L. Myhre, Christian Prebensen, Christine Monceyron Jonassen, Jan Erik Berdal, Torbjørn Omland

Journal of the American Heart Association2021-02-1826 citations

10.1161/jaha.120.019756

Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19

Peder L. Myhre, Christian Prebensen, Heidi Strand, Ragnhild Røysland, Christine Monceyron Jonassen et al. (12 authors)

Circulation2020-10-15108 citations

10.1161/circulationaha.120.050360

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* All patients \>18 years of age with a positive test for SARS-CoV2 are eligble for inclusion. * Healty age-matched volunteers will be included as a control group

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Number of participants with ICU admission or death	From hospital admission (baseline) until the date of either admission to the ICU or death during the index hospitalization (up to 52 weeks)	Combined outcome measure of either ICU admission or death

Secondary

Measure	Time frame	Description
Number of participants with ICU admission	From hospital admission (baseline) until the date of admission to the ICU during the index hospitalization (up to 52 weeks)	ICU admission
Number of participants with death from all causes	From hospital admission (baseline) unitl the date of death during the index hospitalization (up to 52 weeks)	Hospital mortality
Total duration of ICU stay	From admission to the ICU until transfer to another ward, discharge from the hospital or death during the index hospitalization (up to 52 weeks)	Total time admitted to the ICU
Total duration of hospital stay	From hospital admission (baseline) until hospital discharge or death during the index hospitalization (up to 52 weeks)	—

Countries

Norway

Contacts

Primary ContactTorbjørn Omland, MD, PhD

torbjorn.omland@medisin.uio.no67960000

Outcome results